Loading...
Ocean Biomedical, Inc.
OCEAW•NASDAQ
Healthcare
Biotechnology
$0.010
$0.007(276.92%)

Over the past four quarters, Ocean Biomedical, Inc. demonstrated steady revenue growth, increasing from $0.00 in Q4 2023 to $0.00 in Q3 2024. Operating income reached -$768000.00 in Q3 2024, maintaining a consistent N/A margin over recent quarters. Despite fluctuations in R&D and SG&A expenses, EBITDA remained robust at -$5.07M, reflecting operational efficiency. Net income rose to -$5.53M, with EPS at -$0.20. Disciplined expense management helped sustain profitability, highlighting solid overall financial performance.
Unlock 25+ Years of Financial Data
Get access to extended historical data, advanced metrics, and more with our premium plan